Clovis Oncology (CLVSQ) 10-Q2018 Q1 Quarterly report

Filed: 9 May 18, 1:09pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: accelerated, acceleration, admission, adult, answer, AOCI, arrive, ATHENA, attempt, attention, attract, auxiliary, beneficial, borrow, bring, building, buying, care, channel, China, civil, complied, comply, compromise, Concurrently, conference, constitute, constrained, contest, copy, cover, cured, default, diminishing, discourage, disgorgement, diversion, enactment, enhanced, epithelial, explain, exploring, flow, formal, forward, free, fulfill, grace, highly, iii, incremental, incumbent, indemnify, indirect, infrastructure, injunction, injunctive, insufficient, intensify, Japan, labeled, largest, memorialized, mix, month, network, notification, notified, opportunity, oppose, ownership, payor, persuade, post, potent, practice, prevent, priority, progressive, promised, qualify, recapitalizing, recipient, reclassification, refinance, regular, relapsed, repay, repayment, reputation, restate, restructuring, retain, retained, reversal, served, settle, settled, stranded, takeover, temporarily, termination, thereunder, timeline, tolerate, tribunal, typically, uninsured, Union, variable, VEGF, vendor, view, waived, warranted, wrongdoing

Removed: absence, appointed, Arkin, arrangement, assured, attributed, begun, Berger, Bernstein, challenged, collection, dated, decision, decreased, deplete, determinable, disaggregate, discontinuation, discontinue, equally, evidence, flat, Foundation, gastroesophageal, heavily, impacted, investigating, largely, Les, likelihood, Litowitz, Medicine, minimum, misconduct, mutant, occurred, owner, pancreatic, partner, passage, passed, persuasive, purportedly, pursued, recombination, record, reducing, registered, resell, resold, responded, scoping, secondary, seeking, shared, studied, test, title, underwriter, VEGFR, venture, vest, Vested, women

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CLVSQ transcripts

CLVSQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Clovis Oncology, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission (the “Report”), Daniel W. Muehl, as Senior Vice President of Finance and Principal Financial and Accounting Officer of the Company, does hereby certify, pursuant to §906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), that to his knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 9, 2018

/s/ DANIEL W. MUEHL

Daniel W. Muehl

Senior Vice President of Finance and

Principal Financial and Accounting Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.